Marshall Wace, LLP Gamida Cell Ltd. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.87 $15,980 - $35,156	-18,800 Reduced 50.05%	18,761 $19,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $27,419 - $89,019	37,561 New	37,561 $72,000
Q4 2022 Feb 14, 2023	SELL	$1.15 - $2.1 $64,045 - $116,953	-55,692 Reduced 15.1%	313,207 $404,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $220,271 - $488,051	143,968 Added 64.01%	368,899 $586,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $4.29 $67,869 - $168,300	39,231 Added 21.13%	224,931 $398,000

Q1 2022 May 16, 2022	BUY	$2.22 - $4.47 $175,049 - $352,463	78,851 Added 73.8%	185,700 $770,000
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $585,741 - $1.19 Million	-266,246 Reduced 71.36%	106,849 $272,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $6.44 $1.44 Million - $2.4 Million	373,095 New	373,095 $1.46 Million

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.